Greenwich LifeSciences, Inc. (GLSI)
NASDAQ · Healthcare
$14.07-13.79%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $206.52M
- P/E ratio
- —
- EPS
- —
- Volume
- 681,341
- 52-week high
- —
- 52-week low
- —
- Open
- $16.37
- Day high
- $17.20
- Day low
- $13.34
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$2.74M | -$0.21 |
| 2024 | — | -$17.41M | -$1.34 |
| 2023 | — | -$8.89M | -$0.69 |
| 2022 | — | -$7.83M | -$0.61 |
| 2021 | — | -$4.57M | -$0.35 |
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
- CEO
- Snehal S. Patel
- Employees
- 13
- Country
- US
- IPO date
- Sep 25, 2020
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Greenwich LifeSciences, Inc.'s stock price today?
- GLSI is trading at $14.07 as of Jul 20, 2026.
- What is Greenwich LifeSciences, Inc.'s market cap?
- Greenwich LifeSciences, Inc. (GLSI) has a market capitalization of $206.52M.
- Does Greenwich LifeSciences, Inc. pay a dividend?
- Greenwich LifeSciences, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Greenwich LifeSciences, Inc. in?
- Greenwich LifeSciences, Inc. operates in the Healthcare sector.